ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**
Alecensa 150 mg hard capsules

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**
Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

*Excipients with known effect*
Each hard capsule contains 33.7 mg lactose (as monohydrate) and 6 mg sodium (as sodium laurilsulfate).

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**
Hard capsule.

White hard capsule of 19.2 mm length, with “ALE” printed in black ink on the cap and “150 mg” printed in black ink on the body.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

4.2 **Posology and method of administration**
Treatment with Alecensa should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.

A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should be established prior to initiation of Alecensa therapy.

**Posology**
The recommended dose of Alecensa is 600 mg (four 150 mg capsules) taken twice daily with food (total daily dose of 1200 mg).

Patients with underlying severe hepatic impairment (Child-Pugh C) should receive a starting dose of 450 mg taken twice daily with food (total daily dose of 900 mg).

**Duration of treatment**
Treatment with Alecensa should be continued until disease progression or unacceptable toxicity.
Delayed or missed doses
If a planned dose of Alecensa is missed, patients can make up that dose unless the next dose is due within 6 hours. Patients should not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose of Alecensa, patients should take the next dose at the scheduled time.

Dose adjustments
Management of adverse events may require dose reduction, temporary interruption, or discontinuation of treatment with Alecensa. The dose of Alecensa should be reduced in steps of 150 mg twice daily based on tolerability. Alecensa treatment should be permanently discontinued if patients are unable to tolerate the 300 mg twice daily dose.

Dose modification advice is provided in Tables 1 and 2 below.

Table 1 Dose reduction schedule

<table>
<thead>
<tr>
<th>Dose reduction schedule</th>
<th>Dose level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>600 mg twice daily</td>
</tr>
<tr>
<td>First dose reduction</td>
<td>450 mg twice daily</td>
</tr>
<tr>
<td>Second dose reduction</td>
<td>300 mg twice daily</td>
</tr>
</tbody>
</table>

Table 2 Dose modification advice for specified Adverse Drug Reactions (see sections 4.4 and 4.8)

<table>
<thead>
<tr>
<th>CTCAE grade</th>
<th>Alecensa treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILD/pneumonitis of any severity grade</td>
<td>Immediately interrupt and permanently discontinue Alecensa if no other potential causes of ILD/pneumonitis have been identified.</td>
</tr>
<tr>
<td>ALT or AST elevation of Grade ≥ 3 (&gt; 5 times ULN) with total bilirubin ≤ 2 times ULN</td>
<td>Temporarily withhold until recovery to baseline or ≤ Grade 1 (≤ 3 times ULN), then resume at reduced dose (see Table 1).</td>
</tr>
<tr>
<td>ALT or AST elevation of Grade ≥ 2 (&gt; 3 times ULN) with total bilirubin elevation &gt; 2 times ULN in the absence of cholestasis or haemolysis</td>
<td>Permanently discontinue Alecensa.</td>
</tr>
<tr>
<td>Bradycardia* Grade 2 or Grade 3 (symptomatic, may be severe and medically significant, medical intervention indicated)</td>
<td>Temporarily withhold until recovery to ≤ Grade 1 (asymptomatic) bradycardia or to a heart rate of ≥ 60 bpm. Evaluate concomitant medicinal products known to cause bradycardia, as well as anti-hypertensive medicinal products. If a contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to ≤ Grade 1 (asymptomatic) bradycardia or to a heart rate of ≥ 60 bpm. If no contributing concomitant medicinal product is identified, or if contributing concomitant medicinal products are not discontinued or dose is...</td>
</tr>
<tr>
<td>CTCAE grade</td>
<td>Alecensa treatment</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Bradycardia&lt;sup&gt;a&lt;/sup&gt; Grade 4 (life-threatening consequences, urgent intervention indicated)</td>
<td>Permanently discontinue if no contributing concomitant medicinal product is identified. If a contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, resume at reduced dose (see Table 1) upon recovery to ≤ Grade 1 (asymptomatic) bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue in case of recurrence.</td>
</tr>
<tr>
<td>CPK elevation &gt; 5 times ULN</td>
<td>Temporarily withhold until recovery to baseline or to ≤ 2.5 times ULN, then resume at the same dose.</td>
</tr>
<tr>
<td>CPK elevation &gt; 10 times ULN or second occurrence of CPK elevation of &gt; 5 times ULN</td>
<td>Temporarily withhold until recovery to baseline or to ≤ 2.5 times ULN, then resume at reduced dose as per Table 1.</td>
</tr>
</tbody>
</table>

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; CTCAE = NCI Common Terminology Criteria for Adverse Events; ILD = interstitial lung disease; ULN = upper limit of normal

<sup>a</sup>Heart rate less than 60 beats per minute (bpm).

**Special populations**

**Hepatic impairment**

No starting dose adjustment is required in patients with underlying mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Patients with underlying severe hepatic impairment (Child-Pugh C) should receive a starting dose of 450 mg taken twice daily (total dose of 900 mg) (see section 5.2). For all patients with hepatic impairment, appropriate monitoring (e.g. markers of liver function) is advised, see section 4.4.

**Renal impairment**

No dose adjustment is required in patients with mild or moderate renal impairment. Alecensa has not been studied in patients with severe renal impairment. However, since alectinib elimination via the kidney is negligible, no dose adjustment is required in patients with severe renal impairment (see section 5.2).

**Elderly (≥ 65 years)**

The limited data on the safety and efficacy of Alecensa in patients aged 65 years and older do not suggest that a dose adjustment is required in elderly patients (see section 5.2). There are no available data on patients over 80 years of age.

**Paediatric population**

The safety and efficacy of Alecensa in children and adolescents below 18 years of age have not been established. No data are available.
Extreme body weight (>130 kg)
Although PK simulations for Alecensa do not indicate a low exposure in patients with extreme body weight (i.e. >130 kg), alectinib is widely distributed and clinical studies for alectinib enrolled patients within a range of body weights of 36.9–123 kg. There are no available data on patients with body weight above 130 kg.

Method of administration
Alecensa is for oral use. The hard capsules should be swallowed whole, and must not be opened or dissolved. They must be taken with food (see section 5.2).

4.3 Contraindications
Hypersensitivity to alectinib or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Interstitial lung disease (ILD)/pneumonitis
Cases of ILD/pneumonitis have been reported in clinical trials with Alecensa (see section 4.8). Patients should be monitored for pulmonary symptoms indicative of pneumonitis. Alecensa should be immediately interrupted in patients diagnosed with ILD/pneumonitis and should be permanently discontinued if no other potential causes of ILD/pneumonitis have been identified (see section 4.2).

Hepatotoxicity
Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the ULN as well as bilirubin elevations of more than 3 times the ULN occurred in patients in pivotal clinical trials with Alecensa (see section 4.8). The majority of these events occurred during the first 3 months of treatment. In the pivotal Alecensa clinical trials it was reported that three patients with Grade 3-4 AST/ALT elevations had drug induced liver injury. Concurrent elevations in ALT or AST greater than or equal 3 times the ULN and total bilirubin greater than or equal 2 times the ULN, with normal alkaline phosphatase, occurred in one patient treated in Alecensa clinical trials.

Liver function, including ALT, AST, and total bilirubin should be monitored at baseline and then every 2 weeks during the first 3 months of treatment. Thereafter, monitoring should be performed periodically, since events may occur later than 3 months, with more frequent testing in patients who develop aminotransferase and bilirubin elevations. Based on the severity of the adverse drug reaction, Alecensa should be withheld and resumed at a reduced dose, or permanently discontinued as described in Table 2 (see section 4.2).

Severe myalgia and creatine phosphokinase (CPK) elevation
Myalgia or musculoskeletal pain was reported in patients in pivotal trials with Alecensa, including Grade 3 events (see section 4.8).

Elevations of CPK occurred in pivotal trials with Alecensa, including Grade 3 events (see section 4.8). The median time to Grade 3 CPK elevation was 14 days across clinical trials (NP28761, NP28673, BO28984).

Patients should be advised to report any unexplained muscle pain, tenderness, or weakness. CPK levels should be assessed every two weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, Alecensa should be withheld, then resumed or dose reduced (see section 4.2).

Bradydcardia
Symptomatic bradycardia can occur with Alecensa (see section 4.8). Heart rate and blood pressure should be monitored as clinically indicated. Dose modification is not required in case of asymptomatic bradycardia (see section 4.2). If patients experience symptomatic bradycardia or life-threatening events, concomitant medicinal products known to cause bradycardia, as well as anti-hypertensive
medicinal products should be evaluated and Alecensa treatment should be adjusted as described in Table 2 (see sections 4.2 and 4.5, ‘P-gp substrates’ and ‘BCRP substrates’).

**Photosensitivity**
Photosensitivity to sunlight has been reported with Alecensa administration (see section 4.8). Patients should be advised to avoid prolonged sun exposure while taking Alecensa, and for at least 7 days after discontinuation of treatment. Patients should also be advised to use a broad-spectrum Ultraviolet A (UVA)/ Ultraviolet B (UVB) sun screen and lip balm (SPF ≥50) to help protect against potential sunburn.

**Women of child-bearing potential**
Alecensa may cause foetal harm when administered to a pregnant woman. Female patients of child-bearing potential receiving Alecensa, must use highly effective contraceptive methods during treatment and for at least 3 months following the last dose of Alecensa (see sections 4.6 and 5.3).

**Lactose intolerance**
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, a congenital lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

**Sodium content**
This medicinal product contains 48 mg sodium per daily dose (1200 mg), equivalent to 2.4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

### 4.5 Interaction with other medicinal products and other forms of interaction

**Effects of other medicinal products on alectinib**
Based on *in vitro* data, CYP3A4 is the primary enzyme mediating the metabolism of both alectinib and its major active metabolite M4, and CYP3A contributes to 40% – 50% of total hepatic metabolism. M4 has shown similar *in vitro* potency and activity against ALK.

**CYP3A inducers**
Co-administration of multiple oral doses of 600 mg rifampicin once daily, a strong CYP3A inducer, with a single oral dose of 600 mg alectinib reduced alectinib C<sub>max</sub> and AUC<sub>inf</sub> by 51% and 73% respectively and increased M4 C<sub>max</sub> and AUC<sub>inf</sub> 2.20 and 1.79-fold respectively. The effect on the combined exposure of alectinib and M4 was minor, reducing C<sub>max</sub> and AUC<sub>inf</sub> by 4% and 18%, respectively. Based on the effects on the combined exposure of alectinib and M4, no dose adjustments are required when Alecensa is co-administered with CYP3A inducers. Appropriate monitoring is recommended for patients taking concomitant strong CYP3A inducers (including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John’s Wort (Hypericum perforatum)).

**CYP3A inhibitors**
Co-administration of multiple oral doses of 400 mg posaconazole twice daily, a strong CYP3A inhibitor, with a single oral dose of 300 mg alectinib increased alectinib exposure C<sub>max</sub> and AUC<sub>inf</sub> by 1.18 and 1.75-fold respectively, and reduced M4 C<sub>max</sub> and AUC<sub>inf</sub> by 71% and 25% respectively. The effect on the combined exposure of alectinib and M4 was minor, reducing C<sub>max</sub> by 7% and increasing AUC<sub>inf</sub> 1.36-fold. Based on the effects on the combined exposure of alectinib and M4, no dose adjustments are required when Alecensa is co-administered with CYP3A inhibitors. Appropriate monitoring is recommended for patients taking concomitant strong CYP3A inhibitors (including, but not limited to, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole nefazodone, grapefruit or Seville oranges).

**Medicinal products that increase gastric pH**
Multiple doses of esomeprazole, a proton pump inhibitor, 40 mg once daily, demonstrated no clinically relevant effect on the combined exposure of alectinib and M4. Therefore, no dose
adjustments are required when Alecensa is co-administered with proton pump inhibitors or other medicinal products which raise gastric pH (e.g. H2 receptor antagonists or antacids).

**Effect of transporters on alectinib disposition**

M4 is a substrate of P-gp. As alectinib inhibits P-gp, it is not expected that co-medication with P-gp inhibitors has a relevant effect on M4 exposure.

**Effects of alectinib on other medicinal products**

**P-gp substrates**

*In vitro*, alectinib and its major active metabolite M4 are inhibitors of the efflux transporter P-glycoprotein (P-gp). Therefore, alectinib and M4 may have the potential to increase plasma concentrations of co-administered substrates of P-gp. When Alecensa is co-administered with P-gp substrates (e.g., digoxin, dabigatran etexilate, topotecan, sirolimus, everolimus, nilotinib and lapatinib), appropriate monitoring is recommended.

**BCRP substrates**

*In vitro*, alectinib and M4 are inhibitors of the efflux transporter Breast Cancer Resistance Protein (BCRP). Therefore, alectinib and M4 may have the potential to increase plasma concentrations of co-administered substrates of BCRP. When Alecensa is co-administered with BCRP substrates (e.g., methotrexate, mitoxantrone, topotecan and lapatinib), appropriate monitoring is recommended.

**CYP substrates**

*In vitro*, alectinib and M4 show weak time-dependent inhibition of CYP3A4, and alectinib exhibits a weak induction potential of CYP3A4 and CYP2B6 at clinical concentrations.

Multiple doses of 600 mg alectinib had no influence on the exposure of midazolam (2 mg), a sensitive CYP3A substrate. Therefore, no dose adjustment is required for co-administered CYP3A substrates.

A risk for induction of CYP2B6 and PXR regulated enzymes apart from CYP3A4 cannot be completely excluded. The effectiveness of concomitant administration of oral contraceptives may be reduced.

4.6 **Fertility, pregnancy and lactation**

**Women of childbearing potential/contraception**

Women of childbearing potential must be advised to avoid pregnancy while on Alecensa. Female patients of child-bearing potential receiving Alecensa must use highly effective contraceptive methods during treatment and for at least 3 months following the last dose of Alecensa.

**Pregnancy**

There are no or limited amount of data from the use of Alecensa in pregnant women. Based on its mechanism of action, Alecensa may cause foetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity (see section 5.3).

Female patients, who become pregnant while taking Alecensa or during the 3 months following the last dose of Alecensa must contact their doctor and should be advised of the potential harm to the foetus.

**Breast-feeding**

It is unknown whether alectinib and its metabolites are excreted in human milk. A risk to the newborn/infant cannot be excluded. Mothers should be advised against breast-feeding while receiving Alecensa.
Fertility
No fertility studies in animals have been performed to evaluate the effect of Alecensa. No adverse effects on male and female reproductive organs were observed in general toxicology studies (see section 5.3).

4.7 Effects on ability to drive and use machines

Alecensa has minor influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience symptomatic bradycardia (e.g., syncope, dizziness, hypotension) or vision disorders while taking Alecensa (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

The data described below reflect exposure to Alecensa in 405 patients with ALK-positive advanced NSCLC who participated in one randomised Phase III clinical trial (BO28984) and in two single-arm phase II clinical trials (NP28761, NP28673). These patients were treated with the recommended dose of 600 mg twice daily. In the phase II clinical trials (NP28761, NP28673; N=253), the median duration of exposure to Alecensa was 11 months. In BO28984 (ALEX; N=152) the median duration of exposure to Alecensa was 17.9 months, whereas the median duration of exposure to crizotinib was 10.7 months.

The most common adverse drug reactions (ADRs) (≥ 20%) were constipation (35%), oedema (30%, including oedema peripheral, oedema, generalised oedema, eyelid oedema, periorbital oedema, face oedema and localised oedema), and myalgia (28%, including myalgia and musculoskeletal pain).

Tabulated list of adverse drug reactions

Table 3 lists the ADRs occurring in patients who received Alecensa across two phase II clinical trials (NP28761, NP28673) and one phase III clinical trial (BO28984; ALEX), and during post-marketing.

The ADRs listed in Table 3 are presented by system organ class and frequency categories, defined using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000). Within each system organ class, undesirable effects are presented in order of decreasing frequency.

Table 3 ADRs reported in Alecensa clinical trials (NP28761, NP28673, BO28984; N=405) and during post-marketing

<table>
<thead>
<tr>
<th>System organ class</th>
<th>ADRs (MedDRA)</th>
<th>All grades (%)</th>
<th>Frequency category (all grades)</th>
<th>Grades 3-4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Anaemia</td>
<td>17</td>
<td>Very common</td>
<td>3.0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dysgeusia</td>
<td>5.2</td>
<td>Common</td>
<td>0.2</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Vision disorders</td>
<td>8.6</td>
<td>Common</td>
<td>0</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Bradycardia</td>
<td>8.9</td>
<td>Common</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Interstitial lung disease / pneumonitis</td>
<td>0.7</td>
<td>Uncommon</td>
<td>0.2</td>
</tr>
</tbody>
</table>
### Description of selected adverse drug reactions

The safety profile of Alecensa was generally consistent across the pivotal phase III clinical trial BO28984 (ALEX) and phase II trials (NP28761, NP28673).

**Interstitial lung disease (ILD) / pneumonitis**

Severe ILD/pneumonitis occurred in patients treated with Alecensa. Across clinical trials (NP28761, NP28673, BO28984), 1 out of 405 patients treated with Alecensa (0.2%) had a Grade 3 ILD. This event led to withdrawal from Alecensa treatment. In the phase III clinical trial BO28984, Grade 3 or 4...
ILD/pneumonitis was not observed in patients receiving Alecensa versus 2.0% of patients receiving crizotinib. There were no fatal cases of ILD in any of the clinical trials. Patients should be monitored for pulmonary symptoms indicative of pneumonitis (see sections 4.2 and 4.4).

**Hepatotoxicity**

Across clinical trials (NP28761, NP28673, BO28984) two patients with Grade 3-4 AST/ALT elevations had documented drug induced liver injury by liver biopsy. In addition, one patient experienced a Grade 4 adverse event of drug-induced liver injury. Two of these cases led to withdrawal from Alecensa treatment. Adverse reactions of increased AST and ALT levels (15% and 14% respectively) were reported in patients treated with Alecensa across clinical trials (NP28761, NP28673, BO28984). The majority of these events were of Grade 1 and 2 intensity, and events of Grade ≥ 3 were reported in 3.7% and 3.7% of the patients, respectively. The events generally occurred during the first 3 months of treatment, were usually transient and resolved upon temporary interruption of Alecensa treatment (reported for 1.5% and 3.0% of the patients, respectively) or dose reduction (2.2% and 1.2%, respectively). In 1.2% and 1.5% of the patients, AST and ALT elevations, respectively, led to withdrawal from Alecensa treatment. Grade 3 or 4 ALT or AST elevations were each observed in 5% of patients receiving Alecensa versus 15% and 11% of patients receiving crizotinib in the phase III clinical trial BO28984.

Adverse reactions of bilirubin elevations were reported in 18% of the patients treated with Alecensa across clinical trials (NP28761, NP28673, BO28984). The majority of the events were of Grade 1 and 2 intensity; Grade 3 events were reported in 3.2% of the patients. The events generally occurred during the first 3 months of treatment, were usually transient and the majority resolved upon dose modification. In 5.2% of patients, bilirubin elevations led to dose modifications and in 1.5% of patients, bilirubin elevations led to withdrawal from Alecensa treatment. In the phase III clinical trial BO28984, Grade 3 or 4 bilirubin elevations occurred in 3.3% of patients receiving Alecensa versus no patient receiving crizotinib.

Concurrent elevations in ALT or AST greater than or equal to three times the ULN and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in one patient (0.2%) treated in Alecensa clinical trials.

Patients should be monitored for liver function including ALT, AST, and total bilirubin as outlined in section 4.4 and managed as recommended in section 4.2.

**Bradycardia**

Cases of bradycardia (8.9%) of Grade 1 or 2 have been reported in patients treated with Alecensa across clinical trials (NP28761, NP28673, BO28984). No patients had events of Grade ≥ 3 severity. There were 66 of 365 patients (18%) treated with Alecensa who had post-dose heart rate values below 50 beats per minutes (bpm). In the phase III clinical trial BO28984 15% of patients treated with Alecensa had post-dose heart rate values below 50 bpm versus 20% of patients treated with crizotinib. Patients who develop symptomatic bradycardia should be managed as recommended in sections 4.2 and 4.4. No case of bradycardia led to withdrawal from Alecensa treatment.

**Severe myalgia and CPK elevations**

Cases of myalgia (28%) including myalgia events (22%) and musculoskeletal pain (7.4%) have been reported in patients treated with Alecensa across clinical trials (NP28761, NP28673, BO28984). The majority of events were Grades 1 or 2 and three patients (0.7%) had a Grade 3 event. Dose modifications of Alecensa treatment due to these adverse events were only required for two patients (0.5%); Alecensa treatment was not withdrawn due to these events of myalgia. Elevations of CPK occurred in 43% of 362 patients with CPK laboratory data available across clinical trials (NP28761, NP28673, BO28984) with Alecensa. The incidence of Grade 3 elevations of CPK was 3.7%. Median time to Grade 3 CPK elevation was 14 days across trials (NP28761, NP28673, BO28984). Dose modifications for elevation of CPK occurred in 3.2% of patients; withdrawal from Alecensa treatment did not occur due to CPK elevations. Severe myalgia has not been reported in the clinical trial BO28984. Grade 3 elevation of CPK was reported for 2.6% of patients receiving Alecensa and 1.3%
of patients receiving crizotinib; and median time to Grade 3 CPK elevation was 27.5 days and 369 days, respectively, in the pivotal phase III clinical trial BO28984 (ALEX).

**Gastrointestinal effects**
Constipation (35%), nausea (19%), diarrhoea (16%) and vomiting (11%) were the most commonly reported gastrointestinal (GI) reactions. Most of these events were of mild or moderate severity; Grade 3 events were reported for diarrhea (0.7%), nausea (0.5%), and vomiting (0.2%). These events did not lead to withdrawal from Alecensa treatment. Median time to onset for constipation, nausea, diarrhea, and/or vomiting events across clinical trials (NP28761, NP28673, BO28984) was 21 days. The events declined in frequency after the first month of treatment. In the phase III clinical trial BO28984, one patient (0.2%) experienced a Grade 4 event of nausea in the Alecensa arm and the incidence of Grade 3 and 4 events for nausea, vomiting, and diarrhoea was 3.3%, 3.3%, and 2.0%, respectively, in the crizotinib arm.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**
Patients who experience overdose should be closely supervised and general supportive care instituted. There is no specific antidote for overdose with Alecensa.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**
Pharmacotherapeutic group: anti-neoplastic agents, protein kinase inhibitor; ATC code: L01XE36.

**Mechanism of action**
Alectinib is a highly selective and potent ALK and RET tyrosine kinase inhibitor. In preclinical studies, inhibition of ALK tyrosine kinase activity led to blockage of downstream signalling pathways including STAT 3 and PI3K/AKT and induction of tumour cell death (apoptosis).

Alectinib demonstrated *in vitro* and *in vivo* activity against mutant forms of the ALK enzyme, including mutations responsible for resistance to crizotinib. The major metabolite of alectinib (M4) has shown similar *in vitro* potency and activity.

Based on preclinical data, alectinib is not a substrate of p-glycoprotein or BCRP, which are both efflux transporters in the blood brain barrier, and is therefore able to distribute into and be retained within the central nervous system.

**Clinical efficacy and safety**

**ALK positive non-small cell lung cancer**

**Treatment-naive patients**
The safety and efficacy of Alecensa were studied in a global randomised Phase III open label clinical trial (BO28984, ALEX) in ALK-positive NSCLC patients who were treatment naïve. Central testing for ALK protein expression positivity of tissue samples from all patients by Ventana anti-ALK (D5F3) immunohistochemistry (IHC) was required before randomisation into the study.
A total of 303 patients were included in the Phase III trial, 151 patients randomised to the crizotinib arm and 152 patients randomised to the Alecensa arm receiving Alecensa orally, at the recommended dose of 600 mg twice daily.

ECOG PS (0/1 vs. 2), race (Asian vs. non-Asian), and CNS metastases at baseline (yes vs. no) were stratification factors for randomisation. The primary endpoint of the trial was to demonstrate superiority of Alecensa versus crizotinib based on Progression Free survival (PFS) as per investigator assessment using RECIST 1.1. Baseline demographic and disease characteristics for Alecensa were median age 58 years (54 years for crizotinib), 55% female (58% for crizotinib), 55% non-Asian (54% for crizotinib), 61% with no smoking history (65% for crizotinib), 93% ECOG PS of 0 or 1 (93% for crizotinib), 97% Stage IV disease (96% for crizotinib), 90% adenocarcinoma histology (94% for crizotinib), 40% CNS metastases at baseline (38% for crizotinib) and 17% having received prior CNS radiation (14% for crizotinib).

The trial met its primary endpoint at the primary analysis, demonstrating a statistically significant improvement in PFS by investigator. Efficacy data are summarised in Table 4 and the Kaplan-Meier curve for investigator assessed PFS is shown in Figure 1.

Table 4 Summary of efficacy results from study BO28984 (ALEX)

<table>
<thead>
<tr>
<th></th>
<th>Crizotinib N=151</th>
<th>Alecensa N=152</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median duration of follow-up (months)</strong></td>
<td>17.6 (range 0.3 – 27.0)</td>
<td>18.6 (range 0.5 – 29.0)</td>
</tr>
<tr>
<td><strong>Primary efficacy parameter</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFS (INV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with event n (%)</td>
<td>102 (68%)</td>
<td>62 (41%)</td>
</tr>
<tr>
<td>Median (months)</td>
<td>11.1</td>
<td>NE</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[9.1; 13.1]</td>
<td>[17.7; NE]</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td>0.47</td>
</tr>
<tr>
<td>[95% CI]</td>
<td></td>
<td>[0.34, 0.65]</td>
</tr>
<tr>
<td>Stratified log-rank p-value</td>
<td>p &lt;0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary efficacy parameters</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFS (IRC)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with event n (%)</td>
<td>92 (61%)</td>
<td>63 (41%)</td>
</tr>
<tr>
<td>Median (months)</td>
<td>10.4</td>
<td>25.7</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[7.7; 14.6]</td>
<td>[19.9; NE]</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td>0.50</td>
</tr>
<tr>
<td>[95% CI]</td>
<td></td>
<td>[0.36; 0.70]</td>
</tr>
<tr>
<td>Stratified log-rank p-value</td>
<td>p &lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td>**Time to CNS progression (IRC)*, **</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with event n (%)</td>
<td>68 (45%)</td>
<td>18 (12%)</td>
</tr>
<tr>
<td>Cause-specific HR</td>
<td></td>
<td>0.16</td>
</tr>
<tr>
<td>[95% CI]</td>
<td></td>
<td>[0.10; 0.28]</td>
</tr>
<tr>
<td>Stratified log-rank p-value</td>
<td>p &lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td>12-month cumulative incidence of CNS progression (IRC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI]</td>
<td>41.4%</td>
<td>9.4%</td>
</tr>
<tr>
<td></td>
<td>[33.2; 49.4]</td>
<td>[5.4; 14.7]</td>
</tr>
<tr>
<td></td>
<td>Crizotinib N=151</td>
<td>Alecensa N=152</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------------</td>
<td>---------------</td>
</tr>
<tr>
<td>ORR (INV)*, ***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Responders n (%)</td>
<td>114 (75.5%)</td>
<td>126 (82.9%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[67.8; 82.1]</td>
<td>[76.0; 88.5]</td>
</tr>
<tr>
<td>Overall survival*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with event n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (months)</td>
<td>40 (27%)</td>
<td>35 (23%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td>0.76</td>
</tr>
<tr>
<td>[95% CI]</td>
<td></td>
<td>[0.48; 1.20]</td>
</tr>
<tr>
<td>Duration of response (INV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (months)</td>
<td>N=114 11.1</td>
<td>N=126 NE</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[7.9; 13.0]</td>
<td>[NE; NE]</td>
</tr>
<tr>
<td>CNS-ORR in patients with measurable CNS metastases at baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS responders n (%)</td>
<td>11 (50.0%)</td>
<td>17 (81.0%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[28.2; 71.8]</td>
<td>[58.1; 94.6]</td>
</tr>
<tr>
<td>CNS-CR n (%)</td>
<td>1 (5%)</td>
<td>8 (38%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>5.5</td>
<td>17.3</td>
</tr>
<tr>
<td>CNS-DOR, median (months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[2.1, 17.3]</td>
<td>[14.8, NE]</td>
</tr>
<tr>
<td>CNS-ORR in patients with measurable and non-measurable CNS metastases at baseline (IRC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS responders n (%)</td>
<td>15 (25.9%)</td>
<td>38 (59.4%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[15.3; 39.0]</td>
<td>[46.4; 71.5]</td>
</tr>
<tr>
<td>CNS-CR n (%)</td>
<td>5 (9%)</td>
<td>29 (45%)</td>
</tr>
<tr>
<td>CNS-DOR, median (months)</td>
<td>3.7</td>
<td>NE</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[3.2, 6.8]</td>
<td>[17.3, NE]</td>
</tr>
</tbody>
</table>

* Key secondary endpoints part of the hierarchical testing
** Competing risk analysis of CNS progression, systemic progression and death as competing events
*** 2 patients in the crizotinib arm and 6 patients in the alectinib arm had CR
CI = confidence interval; CNS = central nervous system; CR = complete response; DOR = duration of response; HR = hazard ratio; IRC = Independent Review Committee; INV = investigator; NE = not estimable; ORR = objective response rate; PFS = progression free survival

The PFS benefit was consistent for patients with CNS metastases at baseline (HR = 0.40, 95% CI: 0.25-0.64, median PFS for Alecensa = NE, 95% CI: 9.2-NE, median PFS for crizotinib = 7.4 months, 95%CI: 6.6-9.6) and without CNS metastases at baseline (HR = 0.51, 95% CI: 0.33-0.80, median PFS for Alecensa = NE, 95% CI: NE, NE, median PFS for crizotinib = 14.8 months, 95% CI:10.8-20.3), indicating benefit of Alecensa over crizotinib in both subgroups.
Crizotinib pre-treated patients

The safety and efficacy of Alecensa in ALK-positive NSCLC patients pre-treated with crizotinib were studied in two Phase I/II clinical trials (NP28673 and NP28761).

NP28673
Study NP28673 was a Phase I/II single arm, multicentre study conducted in patients with ALK-positive advanced NSCLC who have previously progressed on crizotinib treatment. In addition to crizotinib, patients may have received previous treatment with chemotherapy. A total of 138 patients were included in the phase II part of the study and received Alecensa orally, at the recommended dose of 600 mg twice daily.

The primary endpoint was to evaluate the efficacy of Alecensa by Objective Response Rate (ORR) as per central Independent Review Committee (IRC) assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the overall population (with and without prior exposure of cytotoxic chemotherapy treatments). The co-primary endpoint was to evaluate the ORR as per central IRC assessment using RECIST 1.1 in patients with prior exposure of cytotoxic chemotherapy treatments. A lower confidence limit for the estimated ORR above the pre-specified threshold of 35% would achieve a statistically significant result.

Patient demographics were consistent with that of a NSCLC ALK positive population. The demographic characteristics of the overall study population were 67% Caucasian, 26% Asian, 56% females, and the median age was 52 years. The majority of patients had no history of smoking (70%). The ECOG (Eastern Cooperative Oncology Group) performance status at baseline was 0 or 1 in 90.6% of patients and 2 in 9.4% of patients. At the time of entry in the study, 99% of patients had stage IV disease, 61% had brain metastases and in 96% of patients tumours were classified as adenocarcinoma. Among patients included in the study, 20% of the patients had previously progressed on crizotinib treatment only, and 80% had previously progressed on crizotinib and at least one chemotherapy treatment.
Study NP28761

Study NP28761 was a Phase I/II single arm multicentre study conducted in patients with ALK positive advanced NSCLC who have previously progressed on crizotinib treatment. In addition to crizotinib, patients may have received previous treatment with chemotherapy. A total of 87 patients were included in the phase II part of the study and received Alecensa orally, at the recommended dose of 600 mg twice daily.

The primary endpoint was to evaluate the efficacy of Alecensa by ORR as per central IRC assessment using RECIST version 1.1. A lower confidence limit for the estimated ORR above the pre-specified threshold of 35% would achieve a statistically significant result.

Patient demographics were consistent with that of a NSCLC ALK positive population. The demographic characteristics of the overall study population were 84% Caucasian, 8% Asian, 55% females. The median age was 54 years. The majority of patients had no history of smoking (62%). The ECOG performance status at baseline was 0 or 1 in 89.7% of patients and 2 in 10.3% of patients. At the time of entry in the study, 99% of patients had stage IV disease, 60% had brain metastases and in 94% of patients tumours were classified as adenocarcinoma. Among the patients included in the study, 26% of the patients had previously progressed on crizotinib treatment only, and 74% had previously progressed on crizotinib and at least one chemotherapy treatment.

The main efficacy results from studies NP28673 and NP28761 are summarised in Table 5. A summary of pooled analysis of CNS endpoints is presented in Table 6.
Table 5 Efficacy results from studies NP28673 and NP28761

<table>
<thead>
<tr>
<th></th>
<th>NP28673 Alecensa 600 mg twice daily</th>
<th>NP28761 Alecensa 600 mg twice daily</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median duration of follow-up (months)</strong></td>
<td>21 (range 1 – 30)</td>
<td>17 (range 1 – 29)</td>
</tr>
<tr>
<td><strong>Primary efficacy parameters</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR (IRC) in RE population</td>
<td>N=122 (^a)</td>
<td>N = 67 (^b)</td>
</tr>
<tr>
<td>Responders N (%)</td>
<td>62 (50.8%) [41.6%, 60.0%]</td>
<td>35 (52.2%) [39.7%, 64.6%]</td>
</tr>
<tr>
<td>ORR (IRC) in patients pre-treated with chemotherapy</td>
<td>N = 96</td>
<td></td>
</tr>
<tr>
<td>Responders N (%)</td>
<td>43 (44.8%) [34.6%, 55.3%]</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary efficacy parameters</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOR (IRC)</td>
<td>N = 62</td>
<td>N = 35</td>
</tr>
<tr>
<td>Number of patients with events N (%)</td>
<td>36 (58.1%)</td>
<td>20 (57.1%)</td>
</tr>
<tr>
<td>Median (months)</td>
<td>15.2 [11.2, 24.9]</td>
<td>14.9 [6.9, NE]</td>
</tr>
<tr>
<td>PFS (IRC)</td>
<td>N = 138</td>
<td>N = 87</td>
</tr>
<tr>
<td>Number of patients with events N (%)</td>
<td>98 (71.0%)</td>
<td>58 (66.7%)</td>
</tr>
<tr>
<td>Median duration (months)</td>
<td>8.9 [5.6, 12.8]</td>
<td>8.2 [6.3, 12.6]</td>
</tr>
</tbody>
</table>

CI = confidence interval; DOR = duration of response; IRC = independent review committee; NE = not estimable; ORR = objective response rate; PFS = progression free survival; RE = response evaluable

\(^a\) 16 patients did not have measurable disease at baseline according to the IRC and were not included in the IRC response evaluable population.

\(^b\) 20 patients did not have measurable disease at baseline according to the IRC and were not included in the IRC response evaluable population.

ORR results for studies NP28673 and NP28761 were consistent across subgroups of baseline patient characteristics such as age, gender, race, ECOG performance status, Central Nervous System (CNS) metastasis and prior chemotherapy use, especially when considering the small number of patients in some subgroups.
Table 6 Summary of the pooled analysis of CNS endpoints from studies NP28673 and NP28761

<table>
<thead>
<tr>
<th>CNS Parameters (NP28673 and NP28761)</th>
<th>Alecensa 600 mg twice daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with measurable CNS lesions at baseline</td>
<td>N = 50</td>
</tr>
<tr>
<td>CNS ORR (IRC)</td>
<td></td>
</tr>
<tr>
<td>Responders (%)</td>
<td>32 (64.0%)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[49.2%, 77.1%]</td>
</tr>
<tr>
<td>Complete response</td>
<td>11 (22.0%)</td>
</tr>
<tr>
<td>Partial response</td>
<td>21 (42.0%)</td>
</tr>
<tr>
<td>CNS DOR (IRC)</td>
<td></td>
</tr>
<tr>
<td>Number of patients with events (%)</td>
<td>N=32</td>
</tr>
<tr>
<td>Median (months)</td>
<td>11.1</td>
</tr>
<tr>
<td>[95%CI]</td>
<td>[7.6, NE]</td>
</tr>
</tbody>
</table>

CI = confidence interval; DOR = duration of response; IRC = independent review committee; ORR = objective response rate; NE = not estimable

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Alecensa in all subsets of the paediatric population in lung carcinoma (small cell and non-small cell carcinoma) (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

The pharmacokinetic parameters for alectinib and its major active metabolite (M4) have been characterised in ALK-positive NSCLC patients and healthy subjects. Based on population pharmacokinetic analysis, the geometric mean (coefficient of variation %) steady-state C_max, C_min and AUC_0-12hr for alectinib were approximately 665 ng/mL (44.3%), 572 ng/mL (47.8%) and 7430 ng*h/mL (45.7%), respectively. The geometric mean steady-state C_max, C_min and AUC_0-12hr for M4 were approximately 246 ng/mL (45.4%), 222 ng/mL (46.6%) and 2810 ng*h/mL (45.9%), respectively.

Absorption

Following oral administration of 600 mg twice daily under fed conditions in ALK-positive NSCLC patients, alectinib was absorbed reaching T_max after approximately 4 to 6 hours.

Alectinib steady-state is reached within 7 days with continuous 600 mg twice daily dosing. The accumulation ratio for the twice-daily 600 mg regimen was approximately 6-fold. Population PK analysis supports dose proportionality for alectinib across the dose range of 300 to 900 mg under fed conditions.

The absolute bioavailability of alectinib capsules was 36.9% (90% CI: 33.9%, 40.3%) under fed conditions in healthy subjects.

Following a single oral administration of 600 mg with a high-fat, high-calorie meal, alectinib and M4 exposure was increased by around 3-fold relative to fasted conditions (see section 4.2).

Distribution

Alectinib and its major metabolite M4 are highly bound to human plasma proteins (>99%), independent of active substance concentration. The mean in vitro human blood-to-plasma concentration ratios of alectinib and M4 are 2.64 and 2.50, respectively, at clinically relevant concentrations.

The geometric mean volume of distribution at steady state (Vss) of alectinib following IV administration was 475 L, indicating extensive distribution into tissues.
Based on *in vitro* data, alectinib is not a substrate of P-gp. Alectinib and M4 are not substrates of BCRP or organic anion-transporting polypeptide (OATP) 1B1/B3.

**Biotransformation**

*In vitro* metabolism studies showed that CYP3A4 is the main CYP isozyme mediating alectinib and its major metabolite M4 metabolism, and is estimated to contribute 40-50% of alectinib metabolism. Results from the human mass balance study demonstrated that alectinib and M4 were the main circulating moieties in plasma with 76% of the total radioactivity in plasma. The geometric mean Metabolite/Parent ratio at steady state is 0.399. Metabolite M1b was detected as a minor metabolite from *in vitro* and in human plasma in healthy subjects. Formation of metabolite M1b and its minor isomer M1a is likely to be catalyzed by a combination of CYP isozymes (including isozymes other than CYP3A) and aldehyde dehydrogenase (ALDH) enzymes.

*In vitro* studies indicate that neither alectinib nor its major active metabolite (M4) inhibits CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations. Alectinib did not inhibit OATP1B1/OATP1B3, OAT1, OAT3 or OCT2 at clinically relevant concentrations in vitro.

**Elimination**

Following administration of a single dose of 14C-labeled alectinib administered orally to healthy subjects the majority of radioactivity was excreted in faeces (mean recovery 97.8%) with minimal excretion in urine (mean recovery 0.46%). In faeces, 84% and 5.8% of the dose was excreted as unchanged alectinib or M4, respectively. Based on a population PK analysis, the apparent clearance (CL/F) of alectinib was 81.9 L/hour. The geometric mean of the individual elimination half-life estimates for alectinib was 32.5 hours. The corresponding values for M4 were 217 L/hour and 30.7 hours, respectively.

**Pharmacokinetics in special populations**

**Renal impairment**

Negligible amounts of alectinib and the active metabolite M4 are excreted unchanged in urine (< 0.2% of the dose). Based on a population pharmacokinetic analysis alectinib and M4 exposures were similar in patients with mild and moderate renal impairment and normal renal function. The pharmacokinetics of alectinib has not been studied in patients with severe renal impairment.

**Hepatic impairment**

As elimination of alectinib is predominantly through metabolism in the liver, hepatic impairment may increase the plasma concentration of alectinib and/or its major metabolite M4. Based on a population pharmacokinetic analysis, alectinib and M4 exposures were similar in patients with mild hepatic impairment and normal hepatic function.

Following administration of a single oral dose of 300 mg alectinib in subjects with severe (Child-Pugh C) hepatic impairment, alectinib C\textsubscript{max} was the same and AUC\textsubscript{inf} was 2.2-fold higher compared with the same parameters in matched healthy subjects. M4 C\textsubscript{max} and AUC\textsubscript{inf} was 39% and 34% lower respectively, resulting in a combined exposure of alectinib and M4 (AUC\textsubscript{inf}) 1.8-fold higher in patients with severe hepatic impairment compared with matched healthy subjects.

The hepatic impairment study also included a group with moderate (Child-Pugh B) hepatic impairment, and a modestly higher alectinib exposure was observed in this group compared with matched healthy subjects. The subjects in the Child Pugh B group however did in general not suffer from abnormal bilirubin, albumin or prothrombin time, indicating that they may not be fully representative of moderately hepatically impaired subjects with decreased metabolic capacity.
**Effects of age, body weight, race and gender**

Age, body weight, race and gender had no clinically meaningful effect on the systemic exposure of alectinib and M4. The range of body weights for patients enrolled in clinical studies is 36.9-123 kg. There are no available data on patients with extreme body weight (>130 kg) (see section 4.2).

5.3 Preclinical safety data

**Carcinogenicity**

Carcinogenicity studies have not been performed to establish the carcinogenic potential of Alecensa.

**Mutagenicity**

Alectinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay but induced a slight increase in numerical aberrations in the in vitro cytogenetic assay using Chinese Hamster Lung (CHL) cells with metabolic activation, and micronuclei in a rat bone marrow micronucleus test. The mechanism of micronucleus induction was abnormal chromosome segregation (aneugenicity), and not a clastogenic effect on chromosomes.

**Impairment of fertility**

No fertility studies in animals have been performed to evaluate the effect of Alecensa. No adverse effects on male and female reproductive organs were observed in general toxicology studies. These studies were conducted in rats and monkeys at exposures equal to or greater than 2.6- and 0.5-fold, respectively, of the human exposure, measured by AUC, at the recommended dose of 600 mg twice daily.

**Teratogenicity**

Alectinib caused embryo-foetal toxicity in pregnant rats and rabbits. In pregnant rats, alectinib caused total embryo-foetal loss (miscarriage) at exposures 4.5-fold of the human AUC exposure and small foetuses with retarded ossification and minor abnormalities of the organs at exposures 2.7-fold of the human AUC exposure. In pregnant rabbits, alectinib caused embryo-foetal loss, small fetuses and increased incidence of skeletal variations at exposures 2.9-fold of the human AUC exposure at the recommended dose.

**Other**

Alectinib absorbs UV light between 200 and 400 nm and demonstrated a phototoxic potential in an in vitro photosafety test in cultured murine fibroblasts after UVA irradiation.

Target organs in both rat and monkey at clinically relevant exposures in the repeat-dose toxicology studies included, but were not limited to the erythroid system, gastrointestinal tract, and hepatobiliary system.

Abnormal erythrocyte morphology was observed at exposures equal or greater than 10-60% the human exposure by AUC at the recommended dose. Proliferative zone extension in GI mucosa in both species was observed at exposures equal to or greater than 20-120% of the human AUC exposure at the recommended dose. Increased hepatic alkaline phosphatase (ALP) and direct bilirubin as well as vacuolation/regeneration/necrosis of bile duct epithelium and enlargement/focal necrosis of hepatocytes was observed in rats and/or monkeys at exposures equal to or greater than 20-30% of the human exposure by AUC at the recommended dose.

A mild hypotensive effect has been observed in monkeys at around clinically relevant exposures.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule content
Lactose monohydrate
Hydroxypropylcellulose
Sodium laurilsulfate
Magnesium stearate
Carmellose calcium

Capsule shell
Hypromellose
Carrageenan
Potassium chloride
Titanium dioxide (E171)
Maize starch
Carnauba wax

Printing ink
Red iron oxide (E172)
Yellow iron oxide (E172)
Indigo carmine aluminum lake (E132)
Carnauba wax
White shellac
Glyceryl monooleate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Blisters:
Store in the original package in order to protect from moisture.

Bottles:
Store in the original package and keep the bottle tightly closed in order to protect from moisture.

6.5 Nature and contents of container

Aluminium/aluminium (PA/Alu/PVC/Alu) blisters containing 8 hard capsules.
Pack size: 224 (4 packs of 56) hard capsules.

HDPE bottle with a child-resistant closure and an integrated desiccant.
Pack size: 240 hard capsules.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. **MARKETING AUTHORISATION HOLDER**

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1169/001
EU/1/16/1169/002

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 16 February 2017
Date of latest renewal: 1 December 2017

10. **DATE OF REVISION OF THE TEXT**

ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release
Roche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
GERMANY

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**OUTER CARTON FOR BLISTER**

1. **NAME OF THE MEDICINAL PRODUCT**

   Alecensa 150 mg hard capsules
   alectinib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

3. **LIST OF EXCIPIENTS**

   Contains lactose and sodium. See package leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

   **Hard capsule**
   224 (4 packs of 56) hard capsules

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Oral use
   Read the package leaflet before use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Store in the original package in order to protect from moisture
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1169/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

alecensa

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INTERMEDIATE CARTON FOR BLISTER**

### 1. NAME OF THE MEDICINAL PRODUCT

Alecensa 150 mg hard capsules
alectinib

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

### 3. LIST OF EXCIPIENTS

Contains lactose and sodium. See package leaflet for further information.

### 4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

56 hard capsules

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1169/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

alecensa
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLISTER</strong></td>
</tr>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td>Alecensa 150 mg hard capsules</td>
</tr>
<tr>
<td>alectinib</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
</tr>
<tr>
<td>Roche Registration GmbH</td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
</tr>
<tr>
<td>Lot</td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON FOR BOTTLE

1. NAME OF THE MEDICINAL PRODUCT

Alecensa 150 mg hard capsules
alectinib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

3. LIST OF EXCIPIENTS

Contains lactose and sodium. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule
240 hard capsules

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package and keep the bottle tightly closed in order to protect from moisture
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1169/002

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

alecensa

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOTTLE LABEL</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

Alecensa 150 mg hard capsules  
alectinib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.

3. **LIST OF EXCIPIENTS**

Contains lactose and sodium. See package leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

Hard capsule  
240 hard capsules

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use  
Read the package leaflet before use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

Store in the original package and keep the bottle tightly closed in order to protect from moisture
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1169/002

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine - because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Alecensa is and what it is used for
2. What you need to know before you take Alecensa
3. How to take Alecensa
4. Possible side effects
5. How to store Alecensa
6. Contents of the pack and other information

1. What Alecensa is and what it is used for

What Alecensa is
Alecensa is a cancer medicine that contains the active substance alectinib.

What Alecensa is used for
Alecensa is used to treat adults with a type of lung cancer called ‘non-small cell lung cancer’ (‘NSCLC’). It is used if your lung cancer:
- is ‘ALK-positive’ - this means your cancer cells have a fault in a gene that makes an enzyme called ALK (‘anaplastic lymphoma kinase’), see ‘How Alecensa works’, below
- and is advanced.

Alecensa can be prescribed to you as first treatment of your lung cancer, or if you have been previously treated with a medicine containing ‘crizotinib’.

How Alecensa works
Alecensa blocks the action of an enzyme called ‘ALK tyrosine kinase’. Abnormal forms of this enzyme (due to fault in the gene that makes it) help encourage cancer cell growth. Alecensa may slow down or stop the growth of your cancer. It may also help to shrink your cancer.

If you have any questions about how Alecensa works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.
2. **What you need to know before you take Alecensa**

**Do not take Alecensa:**
- if you are allergic to alectinib or any of the other ingredients of this medicine (listed in section 6).

If you are not sure, talk to your doctor, pharmacist or nurse before taking Alecensa.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Alecensa:
- if you have an inherited problem called ‘galactose intolerance’, ‘congenital lactase deficiency’ or ‘glucose-galactose malabsorption’.

If you are not sure, talk to your doctor, pharmacist or nurse before taking Alecensa.

Alecensa can cause side effects that you need to tell your doctor about straight away. These include:
- liver injury (hepatotoxicity). Your doctor will take blood tests before you start treatment, then every 2 weeks for the first 3 months of your treatment and then less often. This is to check you do not have any liver problems while taking Alecensa. Tell your doctor straight away if you get any of the following signs: yellowing of your skin or the whites of your eyes, pain on the right side of your stomach area, dark urine, itchy skin, feeling less hungry than usual, nausea or vomiting, feeling tired, bleeding or bruising more easily than normal.
- slow heart beat (bradycardia).
- lung inflammation (pneumonitis). Alecensa may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. The signs may be similar to those from your lung cancer. Tell your doctor straight away if you have any new or worsening signs including difficulty in breathing, shortness of breath, or cough with or without mucous, or fever.
- severe muscle pain, tenderness, and weakness (myalgia). Your doctor will do blood tests at least every 2 weeks for the first month and as needed during treatment with Alecensa. Tell your doctor straight away if you get new or worsening signs of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.

Look out for these while you are taking Alecensa. See ‘Side effects’ in section 4 for more information.

**Sensitivity to sunlight**

Do not expose yourself to the sun for any long period of time while you are taking Alecensa and for 7 days after you stop. You need to apply sunscreen and lip balm with a Sun Protection Factor of 50 or higher to help prevent sunburn.

**Children and adolescents**

Alecensa has not been studied in children or adolescents. Do not give this medicine to children or adolescents under the age of 18 years.

**Tests and checks**

When you take Alecensa your doctor will do blood tests before you start treatment, then every 2 weeks for the first 3 months of your treatment and then less often. This is to check you do not have any liver or muscle problems while taking Alecensa.

**Other medicines and Alecensa**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, and herbal medicines. This is because Alecensa can affect the way some other medicines work. Also some other medicines can affect the way Alecensa works.

In particular tell your doctor or pharmacist if you are taking any of the following medicines:
- digoxin, a medicine used to treat heart problems
- dabigatran etexilate, a medicine used to treat blood clots
- methotrexate, a medicine used to treat certain types of cancer or to treat autoimmune diseases (e.g. rheumatoid arthritis)
● nilotinib, a medicine used to treat certain types of cancer
● lapatinib, a medicine used to treat certain types of breast cancer
● mitoxantrone, a medicine used to treat certain types of cancer or autoimmune diseases (e.g. multiple sclerosis)
● everolimus, a medicine used to treat certain types of cancer or used to prevent the body’s immune system from rejecting a transplanted kidney, heart or liver
● sirolimus, a medicine used to prevent the body’s immune system from rejecting a transplanted kidney, heart or liver
● topotecan, a medicine used to treat certain types of cancer
● medicines used to treat AIDS/HIV (e.g. ritonavir, saquinavir)
● medicines used to treat infections. These include medicines that treat fungal infections (antifungals such as ketoconazole, itraconazole, voriconazole, posaconazole) and medicines that treat certain types of bacterial infection (antibiotics such as telithromycin)
● St. John’s Wort, a herbal medicine used to treat depression
● medicines used to stop seizures or fits (anti-epileptics such as phenytoin, carbamazepine, or phenobarbital)
● medicines used to treat tuberculosis (e.g. rifampicin, rifabutin)
● nefazodone, a medicine used to treat depression

Oral contraceptives
If you take Alecensa whilst using oral contraceptives, the oral contraceptives may be less effective.

Alecensa with food and drink
You should use caution when drinking grapefruit juice or eating grapefruit or Seville oranges while on treatment with Alecensa as they may change the amount of Alecensa in your body.

Contraception, pregnancy, and breast-feeding - information for women
Contraception – information for women
● You should not become pregnant while taking this medicine. If you are able to become pregnant, you must use highly effective contraception while on treatment and for at least 3 months after stopping treatment. Talk to your doctor about the right methods of contraception for you and your partner. If you take Alecensa whilst using oral contraceptives, the oral contraceptives may be less effective.

Pregnancy
● Do not take Alecensa if you are pregnant. This is because it may harm your baby.
● If you become pregnant when taking the medicine or during the 3 months after taking your last dose, tell your doctor straight away.

Breast-feeding
● Do not breast-feed while taking this medicine. This is because it is not known if Alecensa can pass over into breast milk and could therefore harm your baby.

Driving and using machines
Take special care when driving and using machines as you may develop problems with vision or slowing of the heartbeat or low blood pressure that can lead to fainting or dizziness while you are taking Alecensa.

Alecensa contains lactose
Alecensa contains lactose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine.

Alecensa contains sodium
This medicine contains 48 mg sodium (main component of cooking/table salt) per recommended daily dose (1200 mg). This is equivalent to 2.4% of the recommended maximum daily dietary intake of sodium for an adult.
3. **How to take Alecensa**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

**How much to take**
- The recommended dose is 4 capsules (600 mg) twice a day.
- This means you take a total of 8 capsules (1200 mg) each day.

If you have severe liver problems before starting your treatment with Alecensa:
- The recommended dose is 3 capsules (450 mg) twice a day.
- This means you take a total of 6 capsules (900 mg) each day.

Sometimes your doctor may lower your dose, stop your treatment for a short time or stop your treatment completely if you feel unwell.

**How to take**
- Alecensa is taken by mouth. Swallow each capsule whole. Do not open or dissolve the capsules.
- You must take Alecensa with food.

**If you vomit after taking Alecensa**
If you vomit after taking a dose of Alecensa, do not take an extra dose, just take your next dose at the usual time.

**If you take more Alecensa than you should**
If you take more Alecensa than you should, talk to a doctor or go to hospital straight away. Take the medicine pack and this leaflet with you.

**If you forget to take Alecensa**
- If it is more than 6 hours until your next dose, take the missed dose as soon as you remember.
- If it is less than 6 hours until your next dose, skip the missed dose. Then take your next dose at the usual time.
- Do not take a double dose to make up for a missed dose.

**If you stop taking Alecensa**
Do not stop taking this medicine without talking to your doctor first. It is important to take Alecensa twice a day for as long as your doctor prescribes it for you.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.

Some side effects could be serious.

**Tell your doctor straight away if you notice any of the following side effects.** Your doctor may lower your dose, stop your treatment for a short time or stop your treatment completely:
- Yellowing of your skin or the whites of your eyes, pain on the right side of your stomach area, dark urine, itchy skin, feeling less hungry than usual, nausea or vomiting, feeling tired, bleeding or bruising more easily than normal (potential signs of liver problems)
- New or worsening signs of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness (potential signs of muscle problems).
- Fainting, dizziness and low blood pressure (potential signs of slow heart beat)
● New or worsening signs including difficulty in breathing, shortness of breath, or cough with or without mucous, or fever - the signs may be similar to those from your lung cancer (potential signs of lung inflammation – pneumonitis). Alecensa can cause severe or life-threatening inflammation of the lungs during treatment.

Other side effects
Tell your doctor, pharmacist or nurse if you notice any of the following side effects:

Very common (may affect more than 1 in 10 people):
● abnormal results of blood tests to check for liver problems (high levels of alanine aminotransferase, aspartate aminotransferase and bilirubin)
● abnormal results of blood tests to check for muscle damage (high level of creatine phosphokinase)
● you may feel tired, weak or short of breath due to a reduction in the number of red blood cells, known as anaemia
● vomiting – if you vomit after taking a dose of Alecensa, do not take an extra dose, just take your next dose at the usual time
● constipation
● diarrhoea
● nausea
● rash
● swelling caused by fluid build-up in the body (oedema)
● weight gain.

Common (may affect up to 1 in 10 people):
● abnormal results of blood tests to check kidney function (high level of creatinine)
● blurred vision, loss of sight, black dots or white spots in your vision, and seeing double (problems with your eyes)
● abnormal results of blood tests to check for liver disease or bone disorders (high level of alkaline phosphatase)
● inflammation of the mucous membrane of the mouth
● sensitivity to sunlight – do not expose yourself to the sun for any long period of time while you are taking Alecensa and for 7 days after you stop. You need to apply sunscreen and lip balm with a Sun Protection Factor of 50 or higher to help prevent sunburn.
● alteration in sense of taste
● rapid loss of kidney function (kidney problems).

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Alecensa

● Keep this medicine out of the sight and reach of children.
● Do not take this medicine after the expiry date which is stated on the carton and either the blister or the bottle after EXP. The expiry date refers to the last day of that month.
● If Alecensa is packed in blisters, store in the original package in order to protect from moisture.
● If Alecensa is packed in bottles, store in the original package and keep the bottle tightly closed to protect from moisture.
● Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What Alecensa contains
- The active substance is alectinib. Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.
- The other ingredients are:
  - **Capsule content:** lactose monohydrate (see section 2 ‘Alecensa contains lactose’), hydroxypropylcellulose, sodium laurilsulfate (see section 2 ‘Alecensa contains sodium’), magnesium stearate and carmelllose calcium
  - **Capsule shell:** hypromellose, carrageenan, potassium chloride, titanium dioxide (E171), maize starch and carnauba wax
  - **Printing ink:** red iron oxide (E172), yellow iron oxide (E172), indigo carmine aluminium lake (E132), carnauba wax, white shellac and glyceryl monooleate.

What Alecensa looks like and contents of the pack
Alecensa hard capsule are white, with ‘ALE’ printed in black ink on the cap and ‘150 mg’ printed in black ink on the body.

The capsules are provided in blisters and are available in cartons containing 224 hard capsules (4 packs of 56). The capsules are also available in plastic bottles containing 240 hard capsules.

Not all pack sizes may be marketed.

Marketing Authorisation Holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Manufacturer
Roche Pharma AG
Emil-Barell-Strasse 1
D-79639 Grenzach-Wyhlen
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
N.V. Roche S.A.
Tél/Tel: +32 (0) 2 525 82 11

Lietuva
UAB “Roche Lietuva”
Tel: +370 5 2546799

България
Рош България ЕООД
Тел: +359 2 818 44 44

Luxembourg/Luxemburg
(Voir/siehe Belgique/Belgien)

Česká republika
Roche s. r. o.
Tel: +420 - 2 20382111

Magyarország
Roche (Magyarország) Kft.
Tel: +36 - 23 446 800

Danmark
Roche a/s
Tlf: +45 - 36 39 99 99

Malta
(See United Kingdom)
Deutschland
Roche Pharma AG
Tel: +49 (0) 7624 140

Nederland
Roche Nederland B.V.
Tel: +31 (0) 348 438050

Eesti
Roche Eesti OÜ
Tel: +372 - 6 177 380

Norge
Roche Norge AS
Tlf: +47 - 22 78 90 00

Ελλάδα
Roche (Hellas) A.E.
Τηλ.: +30 210 61 66 100

Österreich
Roche Austria GmbH
Tel: +43 (0) 1 27739

España
Roche Farma S.A.
Tel: +34 - 91 324 81 00

Polska
Roche Polska Sp.z o.o.
Tel: +48 - 22 345 18 88

Francia
Roche
Tél: +33 (0) 1 47 61 40 00

Polska
Roche Polska Sp.z o.o.
Tel: +48 - 22 345 18 88

Hrvatska
Roche d.o.o.
Tel: +385 1 4722 333

România
Roche România S.R.L.
Tel: +40 21 206 47 01

Ireland
Roche Products (Ireland) Ltd.
Tel: +353 (0) 1 469 0700

Slovenija
Roche farmacevtska družba d.o.o.
Tel: +386 - 1 360 26 00

Ísland
Roche a/s
c/o Icepharma hf
Sími: +354 540 8000

Slovenská republika
Roche Slovensko, s.r.o.
Tel: +421 - 2 52638201

Italia
Roche S.p.A.
Tel: +39 - 039 2471

Suomi/Finland
Roche Oy
Puh/Tel: +358 (0) 10 554 500

Κύπρος
Γ.Α.Στημάτης & Σια Λτδ.
Τηλ.: +357 - 22 76 62 76

Sverige
Roche AB
Tel: +46 (0) 8 726 1200

Latvija
Roche Latvija SIA
Tel: +371 - 6 7039831

United Kingdom
Roche Products Ltd.
Tel: +44 (0) 1707 366000

This leaflet was last revised in {MM/YYYY}.

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: